Literature DB >> 6247426

Macrophage extrinsic antiviral activity during herpes simplex virus infection.

P S Morahan, S S Morse, M G McGeorge.   

Abstract

Peritoneal macrophages from mice infected with herpes simplex virus type 2 (HSV-2) exhibited extrinsic antiviral resistance. When the macrophages were co-cultivated in vitro with virus-infected cells the yield of virus was reduced markedly. Activity was not present 1 to 2 days p.i., peaked at 3 to 4 days, declined by 7 days and was absent at 14 days after HSV-2 infection. The extrinsic antiviral activity was limited to the adherent peritoneal macrophage population. The macrophage antiviral activity was also dose-dependent, with approx. 10(6) macrophages (macrophage: host cell ratio of approx. 2:1) reducing virus plaques by greater than 90% and virus yield 1.5 to 3.0 log10. Comparable extrinsic antiviral activity was also exhibited by Corynebacterium parvum- or thioglycollate-elicited peritoneal macrophages. The macrophage activity was not species-specific, activity on Vero cells or syngeneic mouse embryo fibroblasts being comparable. Activity was also not virus-specific, as the active macrophages also inhibited vesicular stomatitis virus (VSV). The antiviral effects required viable macrophages; cell lysates did not inhibit virus growth.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6247426     DOI: 10.1099/0022-1317-46-2-291

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  26 in total

1.  Evaluation of macrophage antiviral activity in patients affected by neoplasia.

Authors:  R A Merendino; D Iannello; A Arena; L Bonina; V Greco; M Mesiti; S Chillemi; P Mastroeni
Journal:  Med Oncol Tumor Pharmacother       Date:  1988

2.  The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment.

Authors:  W Hans Meisen; Eric S Wohleb; Alena Cristina Jaime-Ramirez; Chelsea Bolyard; Ji Young Yoo; Luke Russell; Jayson Hardcastle; Samuel Dubin; Kamaldeen Muili; Jianhua Yu; Michael Caligiuri; Jonathan Godbout; Balveen Kaur
Journal:  Clin Cancer Res       Date:  2015-03-31       Impact factor: 12.531

3.  Expression of 67,000 MW calcimedin and its binding protein in resident and thioglycolate-elicited macrophages.

Authors:  S S Morse; P B Moore
Journal:  Immunology       Date:  1988-12       Impact factor: 7.397

4.  Nitric oxide and macrophage antiviral extrinsic activity.

Authors:  F Benencia; M C Courreges
Journal:  Immunology       Date:  1999-11       Impact factor: 7.397

5.  Replication of HSV-1 in murine peritoneal macrophages: comparison of various virus strains with different properties.

Authors:  J Görtz; B Brake; V Härle-Grupp; D Falke
Journal:  Arch Virol       Date:  1984       Impact factor: 2.574

6.  Immunity in the female genital tract after intravaginal vaccination of mice with an attenuated strain of herpes simplex virus type 2.

Authors:  M R McDermott; J R Smiley; P Leslie; J Brais; H E Rudzroga; J Bienenstock
Journal:  J Virol       Date:  1984-09       Impact factor: 5.103

7.  Early interactions of herpes simplex virus with mouse peritoneal macrophages.

Authors:  B Svennerholm; A Vahlne; E Lycke
Journal:  Infect Immun       Date:  1982-09       Impact factor: 3.441

8.  Infections of susceptible and resistant mouse strains with herpes simplex virus type 1 and 2.

Authors:  L Caspary; B Schindling; S Dundarov; D Falke
Journal:  Arch Virol       Date:  1980       Impact factor: 2.574

9.  Inhibition of Chlamydia trachomatis replication in HEp-2 cells by human monocyte-derived macrophages.

Authors:  E Manor; I Sarov
Journal:  Infect Immun       Date:  1988-12       Impact factor: 3.441

10.  Expression of immunity to intravaginal herpes simplex virus type 2 infection in the genital tract and associated lymph nodes.

Authors:  M R McDermott; P L Brais; G C PLoettsche; M J Evelegh; C H Goldsmith
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.